Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53.

Loss or mutation of the TP53 tumor suppressor gene is not commonly observed in acute myeloid leukemia (AML), suggesting that there is an alternate route for cell transformation. We investigated the hypothesis that previously observed Bcl-2 family member overexpression suppresses wild-type p53 activity in AML. We demonstrate that wild-type p53 protein is expressed in primary leukemic blasts from patients with de novo AML using 2-dimensional polyacrylamide gel electrophoresis (2D-PAGE) and phospho-specific flow cytometry. We found that p53 was heterogeneously expressed and phosphorylated in AML patient samples and could accumulate following DNA damage. Overexpression of antiapoptosis protein Bcl-2 in AML cells was directly correlated with p53 expression and phosphorylation on serine residues 15, 46, and 392. Within those patients with the highest levels of Bcl-2 expression, we identified a mutation in FLT3 that duplicated phosphorylation site Y591. The presence of this mutation correlated with greater than normal Bcl-2 expression and with previously observed profiles of potentiated STAT and MAPK signaling. These results support the hypothesis that Flt3-mediated signaling in AML enables accumulation of Bcl-2 and maintains a downstream block to p53 pathway apoptosis. Bcl-2 inhibition might therefore improve the efficacy of existing AML therapies by inactivating this suppression of wild-type p53 activity.

[1]  Ø. Bruserud,et al.  Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2:Bax ratio and low levels of heat shock protein 70 and 90. , 2006, Leukemia research.

[2]  E. Heiss,et al.  Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine phosphatase SHP2. , 2006, Blood.

[3]  D. Gilliland,et al.  Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD. , 2006, Blood.

[4]  Nina Anensen,et al.  A Distinct p53 Protein Isoform Signature Reflects the Onset of Induction Chemotherapy for Acute Myeloid Leukemia , 2006, Clinical Cancer Research.

[5]  G. Nolan,et al.  Mapping normal and cancer cell signalling networks: towards single-cell proteomics , 2006, Nature Reviews Cancer.

[6]  R. Hills,et al.  No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. , 2005, Blood.

[7]  Marina Konopleva,et al.  MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. , 2005, Blood.

[8]  G. Gustafsson,et al.  Cellular drug sensitivity in MLL‐rearranged childhood acute leukaemia is correlated to partner genes and cell lineage , 2005, British journal of haematology.

[9]  F. Lo Coco,et al.  Apoptosis and immaturity in acute myeloid leukemia , 2005, Hematology.

[10]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[11]  Jonathan M Irish,et al.  Single Cell Profiling of Potentiated Phospho-Protein Networks in Cancer Cells , 2004, Cell.

[12]  M. Engström,et al.  Phosphatidylinositol 3‐kinase is essential for kit ligand‐mediated survival, whereas interleukin‐3 and flt3 ligand induce expression of antiapoptotic Bcl‐2 family genes , 2003, Journal of leukocyte biology.

[13]  G. Gustafsson,et al.  Increased in vitro cellular drug resistance is related to poor outcome in high‐risk childhood acute lymphoblastic leukaemia , 2003, British journal of haematology.

[14]  Yang Xu,et al.  Regulation of p53 responses by post-translational modifications , 2003, Cell Death and Differentiation.

[15]  Heinz Baumann,et al.  Signal transducer and activator of transcription proteins in leukemias. , 2003, Blood.

[16]  A. Venditti,et al.  Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). , 2003, Blood.

[17]  J. Griffin,et al.  The roles of FLT3 in hematopoiesis and leukemia. , 2002, Blood.

[18]  E. Appella,et al.  Post-translational modifications and activation of p53 by genotoxic stresses. , 2001, European journal of biochemistry.

[19]  J. M. Nørgaard,et al.  Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia , 2001, European Journal of Haematology.

[20]  B. Gjertsen,et al.  In vitro culture of human acute myelogenous leukemia (AML) cells in serum-free media: studies of native AML blasts and AML cell lines. , 2000, Journal of hematotherapy & stem cell research.

[21]  R. Pieters,et al.  Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia. , 2000, Blood.

[22]  P. Coffer,et al.  The role of STATs in myeloid differentiation and leukemia , 2000, Oncogene.

[23]  K. Somasundaram,et al.  Tumor suppressor p53: regulation and function. , 2000, Frontiers in bioscience : a journal and virtual library.

[24]  P. Thall,et al.  The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  P. Koistinen,et al.  p53 status of newly established acute myeloid leukaemia cell lines , 1999, British Journal of Cancer.

[26]  S. Tura,et al.  High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate , 1997, Leukemia.

[27]  K. Orita,et al.  Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23) , 1997, Leukemia.

[28]  T. Hongo,et al.  In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. , 1997, Blood.

[29]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[30]  F. Herrmann,et al.  Mechanisms of p53 alteration in acute leukemias. , 1994, Leukemia.

[31]  J. Magaud,et al.  High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. , 1993, Blood.

[32]  R. Berger,et al.  Mutations of the P53 gene in acute myeloid leukaemia , 1992, British journal of haematology.

[33]  E. Campo,et al.  Appelbaum FR, Rowe JM, Radich J, Dick JE. Acute Myeloid Leukemia. Hematology Am Soc Hematol Educ Program. 2001:62-86. PMID: 11722979 , 2008 .

[34]  T. Sørlie,et al.  Mutation screening of the TP53 gene by temporal temperature gradient gel electrophoresis. , 2005, Methods in molecular biology.

[35]  A. Venditti,et al.  Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemia. , 2004, Haematologica.

[36]  Ø. Bruserud,et al.  Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities. , 2003, Haematologica.

[37]  H. Kantarjian,et al.  Acute myeloid leukemia , 2018, Methods in Molecular Biology.